CHRN EKSO BIONICS HOLDINGS, INC.

CIK 0001549084 23 ready 8-Ks latest May 20, 2026, 5:14 PM ET RSS · JSON

Ready 8-Ks 23

Latest filing May 20, 2026, 5:14 PM ET

Top materiality 0.95

Event mix other_material ×9 · earnings ×6 · m_and_a ×4

Sentiment 4 pos · 4 neg · 15 neu

Latest earnings reported 2025-Q2

Executive change recent →

Recent 8-K filings for CHRN

Highest-materiality recent filing

Ekso Bionics completes reverse merger with Applied Digital subsidiary; renames to ChronoScale Corp.

May 5, 2026, 7:59 PM ET M&A materiality 0.95 neutral item 1.01 item 2.01 item 2.02 item 3.02 item 3.03 item 4.01 item 5.01 item 5.02 item 5.03 item 9.01

Applied Parent & Contributor now hold ~97% of outstanding shares; legacy Ekso holders retain ~3%.
Company issued 138,216,820 new shares to Contributor for 100% of Cloud; post-merger shares outstanding 143,093,381.

Read filing →

May 20, 2026, 5:14 PM ET other material materiality 0.70 neutral item 5.02 item 9.01

ChronoScale Amends Phantom PSU Awards for Three Executives After Change in Control

Scott Davis's Phantom PSU amended to settle as 109,357 shares of common stock plus $1,000,000 cash.
May 5, 2026, 7:59 PM ET M&A materiality 0.95 neutral item 1.01 item 2.01 item 2.02 item 3.02 item 3.03 item 4.01 item 5.01 item 5.02 item 5.03 item 9.01

Ekso Bionics completes reverse merger with Applied Digital subsidiary; renames to ChronoScale Corp.

Applied Parent & Contributor now hold ~97% of outstanding shares; legacy Ekso holders retain ~3%.
May 4, 2026, 7:59 PM ET M&A materiality 0.75 neutral item 1.01 item 3.02 item 3.03 item 5.03 item 9.01

Ekso Bionics to close business combination with Applied Digital, PIPE $15.75M, ticker becomes CHRN

Business combination with Applied Digital subsidiary closes May 5, 2026; company renames to ChronoScale Corporation.
February 17, 2026, 6:59 PM ET M&A materiality 0.95 negative item 1.01 item 2.02 item 3.02 item 3.03 item 5.03 item 5.01 item 5.02 item 9.01

Ekso to merge with Applied Digital Cloud in reverse merger; APLD to own ~97%, rename to ChronoScale

Exchange: Ekso issues 138.2M shares to APLD for 100% of Cloud; APLD expects ~97% ownership of combined company.
January 22, 2026, 6:59 PM ET other material materiality 0.65 neutral item 1.01 item 3.02 item 5.03 item 9.01

Ekso Bionics raises ~$5.3M net via private placement of Series B convertible preferred and warrants

Issued 5,852 shares of Series B Convertible Preferred Stock (stated value $1,000/share) and warrants for 355,960 shares.
December 29, 2025, 6:59 PM ET M&A materiality 0.75 neutral item 7.01 item 8.01 item 9.01

Ekso Bionics and Applied Digital propose business combination; EKSO holders get ~3% of ChronoScale

Applied Digital to spin out cloud business, combine with EKSO to form ChronoScale Corporation.
November 7, 2025, 6:59 PM ET leadership materiality 0.55 neutral item 5.02 item 9.01

Ekso Bionics awards 114.5k RSUs and 257k phantom PSUs to Davis, Wong, Jones; new severance deals

Scott Davis: 80k RSUs + 185k phantom PSUs; severance 9 months (non-CIC) or 18 months salary (CIC).
October 30, 2025, 7:59 PM ET other material materiality 0.60 neutral item 3.02 item 8.01 item 9.01

Ekso Bionics raises $3.2M net in registered direct offering of 769,490 shares at $4.81

Sold 769,490 shares at $4.81 per share to institutional investors; net proceeds ~$3.2M.
October 28, 2025, 7:59 PM ET other material materiality 0.75 negative item 2.02 item 9.01

Ekso Bionics Q3 revenue $4.2M (+2% YoY); exploring sale or acquisition of different industry

Revenue $4.2M, up 2% YoY and 105% sequentially; gross margin 60.3% vs 53.5% last year.
September 17, 2025, 7:59 PM ET debt materiality 0.65 neutral item 1.01 item 1.02 item 2.03 item 9.01

Ekso Bionics enters $2M secured loan with B. Riley at 10% interest

Agreement with B. Riley Commercial Capital for up to $2.0M secured term loan, maturing Sept 14, 2026 or upon qualified equity raise of $2.4M.
July 28, 2025, 7:59 PM ET earnings materiality 0.75 negative item 2.02 item 9.01

Ekso Bionics Q2 revenue falls 58% YoY to $2.1M; net loss $2.7M

Revenue $2.1M vs $5.0M in Q2 2024, down 58% due to lower Enterprise Health device sales.
May 21, 2025, 7:59 PM ET other material materiality 0.60 neutral item 8.01 item 9.01

Ekso Bionics updates reverse stock split effective date to June 2, 2025

Reverse stock split at 1-for-15 effective June 2, 2025; originally planned May 27.
May 20, 2025, 7:59 PM ET other material materiality 0.65 neutral item 5.07 item 8.01 item 9.01

Ekso Bionics approves 1-for-15 reverse stock split effective May 27, 2025 to regain Nasdaq compliance

Reverse split ratio set at 1-for-15; effective 12:01 a.m. PT on May 27, 2025.
May 5, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02 item 9.01

Ekso Bionics Q1 2025 revenue $3.4M, net loss $2.9M; partnerships expand distribution

Revenue of $3.4M down 11% YoY ($3.8M); net loss $2.9M ($0.12/sh) vs $3.4M ($0.20/sh) in Q1 2024.
March 17, 2025, 7:59 PM ET other material materiality 0.75 neutral item 1.01 item 3.02 item 3.03 item 9.01

Ekso Bionics raises $4.15M via warrant exercise; issues new 10.5M-share warrant at $0.4239

Existing holder exercises 9.8M warrants for $4.15M at $0.4239/share; company receives cash proceeds.
March 3, 2025, 6:59 PM ET earnings materiality 0.72 positive item 2.02 item 9.01

Ekso Bionics reports record Q4 revenue $5.1M, net loss improves 25% for FY 2024

Q4 2024 revenue $5.1M, up 5% YoY; gross margin 53%, up 400 bps vs 49% in Q4 2023.
January 13, 2025, 6:59 PM ET earnings materiality 0.60 positive item 2.02 item 8.01 item 9.01

Ekso Bionics expects record Q4 2024 revenue of $5.0-$5.1M, preliminary

Q4 2024 revenue estimated at $5.0-5.1M (company record vs $4.8M in Q4 2023).
December 13, 2024, 6:59 PM ET regulatory materiality 0.80 negative item 3.01

Ekso Bionics receives Nasdaq bid price deficiency notice; has until June 10, 2025 to comply

Nasdaq notice dated Dec 12, 2024: common stock bid price below $1.00 for 31 consecutive business days.
October 28, 2024, 7:59 PM ET earnings materiality 0.55 neutral item 2.02 item 9.01

Ekso Bionics Q3 rev $4.1M (-11% YoY), loss narrows; announces CMS reimbursement

Revenue $4.1M (Q3 2024) vs $4.6M (Q3 2023); 33 EksoHealth devices sold.
September 3, 2024, 7:59 PM ET other material materiality 0.65 neutral item 1.01 item 9.01

Ekso Bionics raises ~$5.1M net in underwritten public offering of units with warrants

Issued 3.1M units at $1.00/unit (share + Series A/B warrants) and 2.9M pre-funded units at $0.9990/unit.
July 29, 2024, 7:59 PM ET earnings materiality 0.60 positive item 2.02 item 9.01

Ekso Bionics reports record Q2 sales of $5.0M; net loss narrows to $0.13 per share

Revenue $5.0M up 5% YoY; gross margin improved to 53% from 48%.
July 26, 2024, 7:59 PM ET other material materiality 0.10 neutral item 5.07

Ekso Bionics board elects annual say-on-pay vote after stockholder advisory frequency vote

Board determined on July 25, 2024 to hold future advisory votes on executive compensation annually.
June 10, 2024, 7:59 PM ET other materiality 0.15 positive item 5.07

Ekso Bionics shareholders approve all proposals at 2024 annual meeting

All five director nominees elected: Scott Davis, Mary Ann Cloyd, Corinna Lathan, Charles Li, Deborah Lafer Scher.